Targeted therapy developed by Hanmi, ‘Olita Tab’ approved as 27th domestic new drug
A Hanmi-developed targeted therapy for lung cancer acquired approval as the 27th domestic new drug.
The Ministry of Food and Drug Safety announced approval of the first domestically-developed targeted therapy for lung cancer, ‘Olita Tab 200mg(olmutinib)’ and ‘Olita Tab 400mg,’ on May 13.
Target...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
